Sun Text
Reach Us +1-479-250-8204
responsive image
Full Text

Possible Roles of the Transglutaminases in the Molecular Mechanisms Responsible for Human Neurodegenerative Diseases

Parente A, Gatta NG, Battipaglia M, Giuliano A, Capolongo F and Gentile V

Published on: 2020-09-27

Abstract

Transglutaminases are a family of Ca2+-dependent enzymes which catalyze post-translational modifications of proteins. The main activity of these enzymes is the cross-linking of glutaminyl residues of a protein/peptide substrate to lysyl residues of a protein/peptide co-substrate. In addition to lysyl residues, other second nucleophilic co-substrates may include monoamines or polyamines (to form mono- or bi-substituted/crosslinked adducts) or -OH groups (to form ester linkages). In absence of co-substrates, the nucleophile may be water, resulting in the net deamidation of the glutaminyl residue. Transglutaminase activity has been suggested to be involved in molecular mechanisms responsible for both physiological and pathological processes. In particular, transglutaminase activity has been shown to be responsible for human autoimmune diseases, and Celiac Disease is just one of them. Interestingly, neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, supranuclear palsy, Huntington’s disease and other polyglutamine diseases, are characterized in part by aberrant cerebral transglutaminase activity and by increased cross-linked proteins in affected brains. Here we describe the possible molecular be responsible for such diseases and the possible use of transglutaminase inhibitors for patients with diseases mechanisms by which these enzymes could characterized by aberrant transglutaminase activity.

Keywords

Transglutaminases; Post-translational modifications of proteins; Neurodegeneration; NF-kB; Neuroinflammation; Transglutaminase inhibitors

Biochemistry Of The Transglutaminases

Transglutaminases (TGs, E.C. 2.3.2.13) are Ca2+-dependent enzymes which catalyze post-translational modifications of proteins. Examples of TG-catalyzed reactions include: (I) acyl transfer between the g-carboxamide group of a protein/polypeptide glutaminyl residue and the e-amino group of a protein/polypeptide lysyl residue; (II) attachment of a polyamine to the g-carboxamide of a glutaminyl residue; (III) deamidation of the g-carboxamide group of a protein/polypeptide glutaminyl residue (Figure 1) [1,2]. The reactions catalyzed by TGs occur by a two-step mechanism (ping-pong type), (Figure 2). The transamidating activity of TGs is activated by the binding of Ca2+, which exposes an active-site cysteine residue. This cysteine residue reacts with the g-carboxamide group of an incoming glutaminyl residue of a protein/peptide substrate to yield a thioacyl-enzyme intermediate and ammonia, (Figure 2, Step 1). The thioacylenzyme intermediate then reacts with a nucleophilic primary amine substrate, resulting in the covalent attachment of the amine-containing donor to the substrate glutaminyl acceptor and regeneration of the cysteinyl residue at the active site, (Figure 2, Step 2). If the primary amine is donated by the e-amino group of a lysyl residue in a protein/polypeptide, a Ne- (g-L-glutamyl)-L-lysine (GGEL) isopeptide bond is formed, (Figure 1, example I). On the other hand, if a polyamine or another primary amine (e.g. histamine, serotonin and others) acts as the amine donor, a g-glutamylpolyamine (or g- glutamylamine) residue is formed, (Figure 1, example II). It is also possible for a polyamine to act as an N,N-bis-(g-Lglutamyl)polyamine bridge between two glutaminyl acceptor residues either on the same protein/polypeptide or between two proteins/polypeptides [3]. If there is no primary amine present, water may act as the attacking nucleophile, resulting in the deamidation of glutaminyl residues to glutamyl residues, (Figure 1, example III).

Figure 1: Examples of reactions catalyzed by TGs: (I) acyl transfer between the γ-carboxamide group of a protein/polypeptide glutaminyl residue and the γ -amino group of a protein/polypeptide lysyl residue; (II) attachment of a polyamine to the γ -carboxamide of a glutaminyl residue; (III) deamidation of the γ -carboxamide group of a protein/polypeptide glutaminyl residue; (IV) GTPase activity; (V) protein disulfide isomerase activity; (VI) protein kinase activity.

Figure 2: Schematic representation of a two-step transglutaminase reaction. Step 1: In the presence of Ca2+, the active-site cysteine residue reacts with the g-carboxamide group of an incoming glutaminyl residue of a protein/peptide substrate to yield a thioacyl-enzyme intermediate and ammonia. Step 2: The thioacyl-enzyme intermediate reacts with a nucleophilic primary amine substrate, resulting in the covalent attachment of the amine-containing donor to the substrate glutaminyl acceptor and regeneration of the cysteinyl residue at the active site. If the primary amine is donated by the e-amino group of a lysyl residue in a protein/polypeptide, a Ne-(g-L-glutamyl)-L-lysine (GGEL) isopeptide bond is formed.

Regarding the physiological roles played by the transglutaminase activity, recently transglutaminase-catalyzed polyamination of tubulin has been shown to stabilize axonal microtubules, suggesting an important role for these reactions also during some physiological processes, such as neurite outgrowth and axon maturation [4]. The reactions catalyzed by TGs occur with little change in free energy and hence should theoretically be reversible. However, under physiological conditions the cross linking reactions catalyzed by TGs are usually irreversible. This irreversibility partly results from the metabolic removal of ammonia from the system and from thermodynamic considerations resulting from altered protein conformation. Some scientific reports suggest that TGs may be able to catalyze the hydrolysis of Ne-(g-L-glutamyl)-L-lysine cross-links (GGEL) isopeptide bonds in some soluble cross-linked proteins. Furthermore, it is likely that TGs can catalyze the exchange of polyamines onto proteins [2]. In TG2 other catalytic activities, such as the ability to hydrolyze GTP (or ATP) into GDP (or ADP) and inorganic phosphate (Figure 1, example IV), a protein disulfide isomerase activity (Figure 1, example V), and a kinase activity which phosphorylates histones, retinoblastoma (RB) and P53 (Figure 1, example VI), are present, while only some of these activities have been identified also in other TGs [5-8]. Numerous experimental findings indicate that some TGs are multifunctional proteins with distinct and regulated enzymatic activities. In fact, under physiological conditions, the transamidation activity of TGs is latent [9,10], while other activities, recently identified, could be present. For example, in some physiological states, when the concentration of Ca2+ increases, the crosslinking activity of TGs may contribute to important biological processes. As previously described, one of the most intriguing properties of some TGs, such as TG2, is the ability to bind and hydrolyze GTP and furthermore, to bind to GTP and Ca2+. GTP and Ca2+ regulate its enzymatic activities, including protein cross-linking, in a reciprocal manner: the binding of Ca2+ inhibits GTP-binding and GTPbinding inhibits the transglutaminase cross-linking activity of the TG2 [5]. Interestingly, TG2 shows no sequence homology with heterotrimeric or low-molecular-weight G-proteins, but there is evidence that TG2 (TG2/Gha) is involved in signal transduction, and, therefore, TG2/Gha should also be classified as a large molecular weight G-protein. Other studies, along with ours, showed that TG2/Gha can mediate the activation of phospholipase C (PLC) by the a1b-adrenergic 3 receptor [10] and can modulate adenylyl cyclase activity [11]. TG2/Gha can also mediate the activation of the d1 isoform of PLC and of maxi-K channels [12]. Interestingly, the signaling function of TG2/Gha is preserved even with the mutagenic inactivation of its crosslinking activity by the mutation of the active site cysteine residue [13].

Molecular Biology Of The Transglutaminases

At least eight different TGs, distributed in the human body, have been identified to date (Table 1) [14-19]. 

Table 1: TGs and their physiological roles when known.

TG

Physiological role

Gene map location

Reference

Factor XIIIa

Blood clotting

6p24-25

[14]

TG 1 (Keratinocyte TG, kTG)

Skin differentiation

14q11.2

[15]

TG 2  (Tissue TG, tTG, cTG)

Apoptosis, cell adhesion, signal transduction

20q11-12

[16]

TG 3 (Epidermal TG, eTG)

Hair follicle differentiation

20p11.2

[17]

TG 4 (Prostate TG, pTG)

Suppression of sperm immunogenicity

3q21-2

[18]

TG 5 (TG X)

Epidermal differentiation

15q15.2

[19]

TG 6 (TG Y)

Central Nervous System Development

20p13

[19]

TG 7 (TG Z)

Unknown function

15q15.2

[19]

Complex gene expression mechanisms regulate the physiological roles that these enzymes play in both the intracellular and extracellular compartments. In the Nervous System, for example, several forms of TGs are simultaneously expressed [20-22]. In these last years, moreover, several alternative splice variants of TGs, mostly in the 3’- end regions, have been identified [23]. Interestingly, some of them are differently expressed in human pathologies, such as Alzheimer’s Disease (AD) [24]. In addition, several MicroRNAs regulating TG2 expression both in inflammatory and neoplastic conditions have been recently identified [25-26]. Very recently, a long non coding RNA inside the type 2 transglutaminase gene, which tightly correlates with the expression of its transcriptional variants, has been reported, suggesting a new possible regulatory molecular mechanism of the TG2 gene expression [27]. On the basis of their ubiquitous expression and their biological roles, we may speculate that the absence of these enzymes would be lethal. However, this does not always seem to be the case, since, for example, null mutants of the TG2 are usually phenotypically normal at birth [12,28,29]. This result may be explained by the expression of other TGs genes that may substitute the TG2 missing isoform, although other TGs isoform mutations have been associated with severe phenotypes, such as lamellar ichthyosis for TG1 isoform mutations. Bioinformatic studies have shown that the primary structures of human TGs share some identities in only few regions, such as the active site and the calcium binding regions. However, high sequence conservation and, therefore, a high degree of preservation of secondary structure among TG2, TG3 and FXIIIa indicate that these TGs all share four-domain tertiary structures which could be similar to those of other TGs [30].

Role Of The Transglutaminases In Neurodegenerative Diseases

Although numerous scientific reports suggest that the transglutaminase activity is involved in the pathogenesis of neurodegenerative diseases, to date, however, still controversial experimental findings about the role of the TGs enzymes in these diseases have been obtained [31-33]. Protein aggregates in affected brain regions are histopathological hallmarks of many neurodegenerative diseases [34]. More than 30 years ago Selkoe et al. [35] suggested that TG activity might contribute to the formation of protein aggregates in AD brain. In support of this hypothesis, tau protein has been shown to be an excellent in vitro substrate of TGs [36,37] and GGEL cross-links have been found in the neurofibrillary tangles and paired helical filaments of AD brains [38]. Interestingly, a recent work showed the presence of bis g-glutamyl putrescine in human CSF, which was increased in Huntington’s Disease (HD) CSF [39]. This is an important evidence that protein/peptides crosslinking by polyamines does indeed occur in the brain, and that this is increased in HD brain. TGs activity has been shown to induce also amyloid b-protein oligomerization [40] and aggregation at physiologic levels [39]. By these molecular mechanisms, TGs could contribute to AD symptoms and progression [41]. Moreover, there is evidence that TGs also contribute to the formation of proteinaceous deposits in Parkinson’s Disease (PD) [42,43], in supranuclear palsy [44,45] and in HD, a neurodegenerative disease caused by a CAG expansion in the affected gene [46]. For example, expanded polyglutamine domains have been reported to be substrates of TG2 [47-49] and therefore aberrant TGs activity could contribute to CAG-expansion diseases, including HD (Figure 3). However, although all these studies suggest the possible involvement of the TGs in the formation of deposits of protein aggregates in neurodegenerative diseases, they do not indicate whether aberrant TGs activity per se directly determines the disease progression. For example, several experimental findings reported that TG2 activity in vitro leads to the formation of soluble aggregates of a-synuclein [50] or polyQ proteins [51,52]. To date, as previously reported, at least ten human CAG-expansion diseases have been described (Table 2) [53-62] and in at least eight of them their neuropathology is caused by the expansion in the number of residues in the polyglutamine domain to a value beyond [35-40].

Figure 3: Possible physiopathological effects of the mutated huntingtin. Some of the physiopathological roles of mutated huntingtin, including the formation of nuclear inclusions, have been described in the Figure. AP2 = adipocyte Protein 2; BAX = bcl-2-like protein 4; BDNF = brain-derived neurotrophic factor; CALM = calmodulin; CASP = caspases; CASP3 = caspase 3; CASP8 = caspase 8; CBP = CREB binding protein; CBS = cystathionine-β-synthase; DCTN1 = dynactin subunit 1; GAPD = glyceraldehyde-3-phosphate dehydrogenase; GRB2 = growth factor receptor-bound protein 2; HAP1 = huntingtin associated protein 1; HIP1 = huntingtin interacting protein 1; HIP2 = huntingtin interacting protein 2; Hippi =; HIP1 protein interactor; NCOR1 = nuclear receptor corepressor 1; RasGAP = p21Ras protein and GTPase-activating protein complex; TGs = transglutaminases; TP53 = tumor protein 53.

Table 2: List of polyglutamine (CAG-expansion) diseases.

Disease

Sites of neuropathology

CAG triplet number

Gene product
(Intracellular
localization of
protein deposits)

Reference

Normal

Disease

Corea Major or
Huntington’s Disease
(HD)

Striatum (medium spiny neurons)
and cortex in late stage

6–35

36–121

Huntingtin(n,c)

[53]

Spinocerebellar Ataxia
Type 1 (SCA1)

Cerebellar cortex (Purkinje cells), dentate nucleus and brain stem

6–39

40–81

Ataxin-1(n,c)

[54]

Spinocerebellar Ataxia Type 2 (SCA2)

Cerebellum, pontine nuclei, substantia nigra

15–29

35–64

Ataxin–2 (c)

[55]

Spinocerebellar Ataxia Type 3 (SCA3) or Machado-Joseph disease (MJD)

Substantia nigra, globus pallidus, pontine nucleus, cerebellar cortex

13–42

61–84

Ataxin –3 (c)

[56]

Spinocerebellar Ataxia Type 6 (SCA6)

Cerebellar and mild brainstem atrophy

4–18

21–30

Calcium channel Subunit (α 1A)(m)

[57]

Spinocerebellar Ataxia Type 7 (SCA7)

Photoreceptor and bipolar cells, cerebellar cortex, brainstem

7–17

37–130

Ataxin-7 (n)

[58]

Spinocerebellar Ataxia Type 12 (SCA12)

Cortical, cerebellar atrophy

7–32

41–78

Brain specific regulatory subunit of protein phosphatase PP2A (?)

[59]

Spinocerebellar Ataxia Type 17 (SCA17)

Gliosis and neuronal loss in the Purkinje cell layer

29–42

46–63

TATA-binding protein (TBP) (n)

[60]

Spinobulbar Muscular Atrophy (SBMA) or Kennedy Disease

Motor neurons (anterior horn cells, bulbar neurons) and dorsal root ganglia

11–34

40–62

Androgen receptor (n, c)

[61]

Dentatorubralpallidoluysian Atrophy (DRPLA)

Globus pallidus, dentato-rubral and subthalamic nucleus

7–35

49–88

Atrophin (n, c)

[62]

Cellular localization: c, cytosol; m, membrane; n, nucleus

Remarkably, the mutated proteins have no obvious similarities except for the expanded polyglutamine domain. In fact, in all cases except SCA 12, the mutation occurs in the coding region of the gene. However, in SCA12, the CAG triplet expansion occurs in the untranslated region at the 5' end of the PPP2R2B gene. It has been proposed that the toxicity results from overexpression of the brain specific regulatory subunit of protein phosphatase PP2A [59]. Most of the mutated proteins are widely expressed both within the brain and elsewhere in the body. A major challenge then is to understand why the brain is primarily affected and why different regions within the brain are affected in the different CAG-expansion diseases, i.e., what accounts for the neurotoxic gain of function of each protein and for a selective vulnerability of each cell type. Possibly, the selective vulnerability [63] may be explained in part by the susceptibility of the expanded polyglutamine domains in the various CAG-expansion diseases to act as cosubstrates for brain TGs (Figure 4). To strengthen the possible central role of the TGs in neurodegenerative diseases, a study by Hadjivassiliou et al. [64] showed that anti-TG2 IgA antibodies are present in the gut and brain of patients with gluten ataxia, a non-genetic sporadic cerebellar ataxia, but not in ataxia control patients. Recently, anti-TG2, -TG3 and - TG6 antibodies have been found in sera from Celiac Disease patients, suggesting a possible involvement also of other TGs in the pathogenesis of dermatitis herpetiformis and gluten ataxia, two frequent extra intestinal manifestations of gluten sensitivity [65,66]. These last findings could suggest also a possible role of the “gut-brain axe” for the etiopathogenesis of human neurodegenerative diseases, in which the TGs enzymes, in particular the TG2 enzyme, could play an important role [67-69]. In support of the hypothesis of the toxic effect of TGs activity in other neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s Disease, TG activity has been shown to induce amyloid beta-protein and a-synuclein oligomerization and aggregation at physiologic levels [70-72]. In fact, TGs activity induces protofibril-like amyloid betaprotein assemblies that are protease-resistant and inhibit long-term potentiation [41]. Therefore, by these molecular mechanisms, TGs activity could also contribute to Alzheimer's disease symptoms and progression. Recently, TG2 and its product isopeptide have been found increased in Alzheimer’s disease and APPswe/PS1dE9 double transgenic mice brains [73], while catalytically active TG2 colocalizes with Ab pathology in Alzheimer’s disease mouse models [74].

Interestingly, other works are suggesting that also other TGs could be involved in the molecular mechanisms responsible for neurodegenerative diseases [75]. In particular, a work by Basso et al. [76] found that in addition to TG2, TG1 gene expression level is significantly induced following stroke in vivo or due to oxidative stress in vitro. Moreover, structurally diverse inhibitors, used at concentrations that inhibit TG1 and TG2 simultaneously, are neuroprotective. Together, these last studies suggested that multiple TG isoforms, not only TG2, participate in oxidative stress-induced cell death signalling, and that isoform nonselective inhibitors of TGs will be most efficacious in combating oxidative death in neurological disorders. These are interesting and worthwhile studies, suggesting that multiple TGs isoforms can participate in neuronal death processes. Therefore, all these studies suggest that the involvement of brain TGs could represent a common denominator in several neurological diseases, which can lead to the determination of pathophysiological consequences through different molecular mechanisms.

Figure 4: Possible mechanisms responsible for protein aggregate formation catalyzed by TGs. Transglutaminase activity could produce insoluble aggregates both by the formation of Ne-(g-L-glutamyl)-L-lysine (GGEL) isopeptide bonds (left side of the figure) and by the formation of N,N-bis-(g-L-glutamyl)polyamine bridges (right side of the figure) in the mutated huntingtin.

Role of the Transglutaminase Activity in Neuroinflammation

Neuroinflammation

Neuroinflammation plays an important role in various chronic neurodegenerative diseases, characterized also by the pathological accumulation of specific protein aggregates. In particular, several of these proteins have been shown to be substrates of TGs. Interestingly, it has recently been demonstrated that TG2 may also be involved in molecular mechanisms underlying inflammation. In the central nervous system, astrocytes and microglia are the cell types mainly involved in this inflammatory process. The transcription factor NF-κB is considered the main regulator of inflammation and it is activated by a variety of stimuli including calcium influx, oxidative stress and inflammatory cytokines. Recently, in addition to these stimuli, TG2 has been shown to activate NF-kB both via a canonical pathway [77] and via a non-canonical pathway [78]. On the other hand, NF-kB regulatory response elements are present also in the Transglutaminase 2 promoter [79]. Under these conditions, the over-expression of TG2 results in the sustained activation of NF-κB. Several findings emphasize the possible role of the TG2/NF-κB activation pathway in neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis and amyotrophic lateral sclerosis. Together, these evidences suggest that TG2 could play a role in neuroinflammation and could contribute to the production of compounds that are potentially deleterious to neuronal cells.

Transglutaminase Inhibition As Possible Therapeutic Approach

In consideration to the fact that up to now there have been no long-term effective treatments for the human neurodegenerative diseases, then the possibility that selective TGs inhibitors may be of clinical benefit has been seriously considered. In this respect, some encouraging results have been obtained with TGs inhibitors in preliminary studies with different biological models of CAG-expansion diseases. For example, cystamine (Figure 5) is a potent in vitro inhibitor of enzymes which require an unmodified cysteine at the active site [80].

Figure 5: Chemical structure of cystamine.

Inasmuch as TGs contain a crucial active-site cysteine, cystamine has the potential to inhibit these enzymes by a sulfide-disulfide interchange reaction. A sulfidedisulfide interchange reaction results in the formation of cysteamine and a cysteamine-cysteine mixed disulfide residue at the active site. Recent studies have shown that cystamine decreases the number of protein inclusions in transfected cells expressing the atrophin (DRPLA) protein containing a pathological-length polyglutamine domain [81]. In other studies, cystamine administration to HD-transgenic mice resulted in an increase in life expectancy and amelioration of neurological symptoms [82,83]. Neuronal inclusions were decreased in one of these studies [83]. Although all these scientific reports seem to support the hypothesis of a direct role of transglutaminase activity in the pathogenesis of the polyglutamine diseases, cystamine is also found to act in the HD-transgenic mice by mechanisms other than the inhibition of TGs, such as the inhibition of caspases [84], suggesting that this compound can have an additive effect in the therapy of HD. Currently, cysteamine is already in phase I studies in humans with HD [85], but several side effects, such as nausea, motor impairment and dosing schedule have been reported as reasons for non-adherence during phase II studies in human patients affected by cystinosis [86,87]. Another critical problem in the use of TGs inhibitors in treating neurological diseases relates to the fact that, as previously reported, the human brain contains at least four TGs, including TG1, 2, 3 [22] and TG6 [88], and a strong non-selective inhibitor of TGs might also inhibit plasma Factor XIIIa, causing a bleeding disorder. Therefore, from a number of standpoints it would seem that a selective inhibitor, which discriminates between TGs, would be preferable to an indiscriminate TG inhibitor. In fact, although most of the TGs activity in mouse brain, at least as assessed by an assay that measures the incorporation of radioactive putrescine (amine donor) into N,N-dimethyl casein (amine acceptor), seems to be due to TG2 [89], several conflicting data have been obtained by TG2 gene knock-out experiments about the involvement of TG2 in the development of the symptoms of neurodegenerative diseases in transgenic mice models, such as HD- and a-synuclein-transgenic mice [29,90-92]. In addition, a scientific report showed that cystamine reduces aggregate formation in a mouse model of oculopharyngeal muscular dystrophy (OMPD), in which also the TG2 knockdown is capable of suppressing the aggregation and the toxicity of the mutant protein PABPN1 [93], suggesting this compound as a possible therapeutic for OMPD.

Conclusions

Numerous scientific reports have implicated aberrant TGs activity in neurodegenerative diseases, but still today we are looking for experimental findings which could definitely confirm the direct involvement of TGs in the pathogenetic mechanisms responsible for these diseases. However, as result of the putative role of specific TGs isoforms, such as TG2, in some human diseases, there is a considerable interest in developing inhibitors of these enzymes. Of those currently available, cystamine is the most commonly used experimentally to inhibit TG2 activity. In addition to cystamine, several types of TG2 inhibitors have been developed up to now. For example, some of these inhibitors have shown promising results in experimental diabetic models [94], while, very recently, two new small TG2 activity inhibitors, BJJF078 and ERW1041E, have been characterized as possible therapeutic agents in a mouse model for multiple sclerosis [95]. Therefore, the use of these inhibitors of TGs could be then useful also for other clinical approaches. To minimize the possible side effects, however, more selective inhibitors of the TGs should be required in the future. Progress in this area of research could be achieved, if possible, also through pharmaco-genetic approaches.

List of Abbreviations

AD: Alzheimer’s Disease; GGEL: Ne-(g-L-glutamyl)-L-lysine; HD: Huntington’s Disease; PD: Parkinson’s Disease; TGs: Transglutaminases

Acknowledgements

This work is supported by the Italian Education Department and the Regione Campania, Italy (L.R. n.5 del 28.03.2002, finanziamento 2008) entitled: Identificazione e caratterizzazione di geni della transglutaminasi nel Sistema Nervoso in relazione allo sviluppo di malattie neurodegenerative (Identification and characterization of transglutaminase genes in the Nervous System in relationship to the development of neurodegenerative diseases).

References

  1. Folk JE. Mechanism and basis for specificity of transglutaminase-catalyzed e-(g-glutamyl) lysine bond formation. Adv Enzymol Relat Areas Mol Biol. 1983; 54: 1-56.
  2. Lorand L, Conrad SM. Transglutaminases. Mol Cell Biochem. 1984; 58: 9-35.
  3. Piacentini M, Martinet N, Beninati, S, Folk JE. Free and protein conjugated-polyamines in mouse epidermal cells. Effect of high calcium and retinoic acid. J Biol Chem. 1988; 263: 3790-3794 .
  4. Song Y, Kirkpatrick LL, Schilling AB, Helseth DL, Chabot N, Keillor JW, et al. Transglutaminase and polyamination of tubulin: posttranslational modification for stabilizing axonal microtubules. Neuron. 2013; 78: 109-123.
  5. Achyuthan KE, Greenberg CS. Identification of a guanosine triphosphate-binding site on guinea pig liver transglutaminase. Role of GTP and calcium ions in modulating activity. J Biol Chem. 1987; 262: 1901-1906.
  6. Hasegawa G, Suwa M, Ichikawa Y, Ohtsuka T, Kumagai S, Kikuchi M, et al. A novel function of tissue-type transglutaminase: protein disulfide isomerase. Biochem J. 2003; 373: 793-803.
  7. Lahav J, Karniel E, Bagoly Z, Sheptovitsky V, Dardik R, Inbal A. Coagulation factor XIII serves as protein disulfide isomerase. Thromb Haemost. 2009; 101: 840-844.
  8. Iismaa SE, Mearns BM, Lorand L, Graham RM. Transglutaminases and disease: lessons from genetically engineered mouse models and inherited disorders. Physiol Rev. 2009; 89: 991-1023.
  9. Smethurst PA, Griffin M. Measurement of tissue transglutaminase activity in a permeabilized cell system: its regulation by calcium and nucleotides. Biochem J. 1996; 313: 803-808.
  10. Nakaoka H, Perez DM, Baek KJ, Das T, Husain A, Misono K, et al. Gh: a GTP-binding protein with transglutaminase activity and receptor signalling function. Science. 1994; 264: 1593-1596.
  11. Gentile V, Porta R, Chiosi E, Spina A, Caputo I, Valente F, et al. Tissue transglutaminase and adenylate cyclase interactions in Balb-C 3T3 fibroblast membranes. Biochim Biophys Acta. 1997; 1357: 115-122.
  12. Nanda N, Iismaa SE, Owens WA, Husain A, Mackay F, Graham, R.M. Targeted inactivation of Gh/tissue transglutaminase II. J Biol Chem. 2001; 276: 20673-20678.
  13. Mian S, El Alaoui S, Lawry J, Gentile V, Davies PJA, Griffin M. The importance of the GTP binding protein tissue transglutaminase in the regulation of cell cycle progression. FEBS Letters. 1995; 370: 27-31.
  14. Olaisen B, Gedde-Dahl TJR, Teisberg P, Thorsby E, Siverts A, Jonassen R, et al. A structural locus for coagulation factor XIIIA (F13A) is located distal to the HLA region on chromosome 6p in man. Am J Hum Genet. 1985; 37: 215-220.
  15. Yamanishi K, Inazawa J, Liew FM, Nonomura K, Ariyama T, Yasuno H, et al. Structure of the gene for human transglutaminase 1. J Biol Chem. 1992; 267: 17858-17863.
  16. Gentile V, Davies PJA, Baldini A. The human tissue transglutaminase gene maps on chromosome 20q12 by in situ fluorescence hybridization. Genomics. 1994; 20: 295-297.
  17. Wang M, Kim IG, Steinert PM, McBride OW. Assignment of the human transglutaminase 2 (TGM2) and transglutaminase 3 (TGM3) genes to chromosome 20q11.2. Genomics. 1994; 23: 721-722.
  18. Gentile V, Grant F, Porta R, Baldini A. Human prostate transglutaminase is localized on chromosome 3p21.33-p22 by in situ fluorescence hybridization. Genomics. 1995; 27: 219-220.
  19. Grenard P, Bates MK, Aeschlimann D. Evolution of transglutaminase genes: identification of a transglutaminases gene cluster on human chromosome 15q. Structure of the gene encoding transglutaminase X and a novel gene family member, transglutaminase Z. J Biol Chem. 2001; 276: 33066-33078.
  20. Thomas H, Beck K, Adamczyk M, Aeschlimann P, Langley M, Oita RC, et al. Transglutaminase 6: a protein associated with central nervous system development and motor function. Amino Acids. 2013; 44: 161-177.
  21. Bailey CDC, Johnson GVW. Developmental regulation of tissue transglutaminase in the mouse forebrain. J Neurochem 2004; 91: 1369-1379.
  22. Kim SY, Grant P, Lee JHC, Pant HC, Steinert PM. Differential expression of multiple transglutaminases in human brain. Increased expression and cross-linking by transglutaminase 1 and 2 in Alzheimer’s disease. J Biol Chem. 1999; 274: 30715-30721.
  23. Iannaccone M, Giuberti G, De Vivo G, Caraglia M, Gentile V. Identification of a FXIIIA variant in human neuroblastoma cell lines. Int J Biochem Mol Biol. 2013; 4: 102-107.
  24. Citron BA, Santa Cruz KS, Davies PJ, Festoff BW. Intron-exon swapping of transglutaminase mRNA and neuronal tau aggregation in Alzheimer’s disease. J Biol Chem. 2001; 276: 3295-3301.
  25. Eom S, Kim Y, Misun Ki, Park D, Lee H, Lee YS, et al. Transglutaminase II/MicroRNA-218/-181a loop regulates positive feedback relationship between allergic inflammation and tumor metastasis. J Biol Chem. 2014; 289: 29483- 29505.
  26. Shan H, Zhou X, Chen C. MicroRNA-214 suppresses the viability, migration and invasion of human colorectal carcinoma cells via targeting transglutaminase. Molecular Med Rep. 2019; 20: 1459-1467.
  27. Minotti L, Baldassari F, Galasso M, Volinia S, Bergamini CM, Bianchi N. A long non-coding RNA inside the type 2 transglutaminase gene tightly correlates with the expression of its transcriptional variants. Amino Acids. 2018; 50: 421-438.
  28. De Laurenzi V, Melino G. Gene disruption of tissue transglutaminase. Mol Cell Biol. 2001; 21: 148-155.
  29. Mastroberardino PG, Iannicola C, Nardacci R, Bernassola F, De Laurenzi V, Melino G. ‘Tissue’ transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington’s disease. Cell Death Differ. 2002; 9: 873-880.
  30. Lorand L, Graham RM. Transglutaminases: crosslinking enzymes with pleiotropic functions. Nature Mol Cell Biol. 2003; 4: 140-156.
  31. Wolf J, Jäger C, Lachmann I, Schönknecht P, Morawski M, Arendt T, et al. Tissue transglutaminase is not a biochemical marker for Alzheimer’s disease. Neurobiol Aging. 2013; 34: 2495-2498.
  32. Wilhelmus MMM, Drukarch B. Tissue transglutaminase is a biochemical marker for Alzheimer’s disease. Neurobiol Aging. 2014; 35: 3-4.
  33. Wolf J, Jäger C, Morawski M, Lachmann I, Schönknecht P, Mothes T, et al. Tissue transglutaminase in Alzheimer’s disease facts and fiction: a reply to “Tissue transglutaminase is a biochemical marker for Alzheimer’s disease”. Neurobiol Aging. 2014; 35: 5-9.
  34. Adams, R.D.; Victor M. Principles of Neurology, McGraw-Hill, Inc. Ed, 1993.
  35. Selkoe DJ, Abraham C, Ihara Y. Alzheimer’s disease: insolubility of partially purified paired helical filaments in sodium dodecyl sulfate and urea. Proc Natl Acad Sci USA. 1982; 79: 6070-6074.
  36. Grierson AJ, Johnson GV, Miller CC. Three different human isoforms and rat neurofilament light, middle and heavy chain proteins are cellular substrates for transglutaminase. Neurosci Lett. 2001; 298: 9-12.
  37. Singer SM, Zainelli GM, Norlund MA. Transglutaminase bonds in neurofibrillary tangles and paired helical filament t early in Alzheimer’s disease. Neurochem Int. 2002; 40: 17-30.
  38. Halverson RA, Lewis J, Frausto S, Hutton M, Muma NA. Tau protein is cross-linked by transglutaminase in P301L tau transgenic mice. J Neurosci. 2005; 25: 1226-1233.
  39. Jeitner TM, Matson WR, Folk JE, Blass JP, Cooper AJL. Increased levels of g-glutamylamines in Huntington disease CSF. J Neurochem. 2008; 106: 37-44.
  40. Dudek SM, Johnson GV. Transglutaminase facilitates the formation of polymers of the beta-amyloid peptide. Brain Res. 1994; 651: 129-33.
  41. Hartley DM, Zhao C, Speier AC, Woodard GA, Li S, Li Z, et al. Transglutaminase induces protofibril-like amyloid b protein assemblies that are protease-resistant and inhibit long-term potentiation. J Biol Chem. 2008; 283: 16790- 16800.
  42. Citron BA, Suo Z, SantaCruz K, Davies PJ, Qin F, Festoff BW. Protein crosslinking, tissue transglutaminase, alternative splicing and neurodegeneration. Neurochem Int. 2002; 40: 69-78.
  43. Junn, E, Ronchetti RD, Quezado MM, Kim SY, Mouradian MM. Tissue transglutaminase-induced aggregation of a- synuclein: Implications for Lewy body formation in Parkinson’s disease and dementia with Lewy bodies. Proc Natl Acad Sci USA. 2003; 100: 2047-2052.
  44. Zemaitaitis MO, Lee JM, Troncoso JC, Muma NA. Transglutaminase-induced cross-linking of t proteins in progressive supranuclear palsy. J Neuropathol Exp Neurol. 2000; 59: 983-989.
  45. Zemaitaitis MO, Kim SY, Halverson RA, Troncoso JC, Lee JM, Muma NA. Transglutaminase activity, protein, and mRNA expression are increased in progressive supranuclear palsy. J Neuropathol Exp Neurol. 2003; 62: 173-184.
  46. Iuchi S, Hoffner G, Verbeke P, Djian P, Green H. Oligomeric and polymeric aggregates formed by proteins containing expanded polyglutamine. Proc Natl Acad Sci USA. 2003; 100: 2409-2414.
  47. Gentile V, Sepe C, Calvani M, Melone MAB, Cotrufo R, Cooper AJL, et al. Tissue transglutaminase-catalyzed formation of high-molecular-weight aggregates in vitro is favored with long polyglutamine domains: a possible mechanism contributing to CAG-triplet diseases. Arch Biochem Biophys. 1998; 352: 314-321.
  48. Kahlem P, Green H, Djian P. Transglutaminase action imitates Huntington’s disease: selective polymerization of huntingtin containing expanded polyglutamine. Mol Cell. 1998; 1: 595-601.
  49. Karpuj MV, Garren H, Slunt H, Price DL, Gusella J, Becher MW, et al. Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington’s disease brain nuclei. Proc Natl Acad Sci USA. 1999; 96: 7388-7393.
  50. Segers-Nolten IM, Wilhelmus MM, Veldhuis G, van Rooijen BD, Drukarch B, Subramaniam V. Tissue transglutaminase modulates a-synuclein oligomerization. Protein Sci. 2008; 17: 1395-1402.
  51. Lai TS, Tucker T, Burke JR, Strittmatter WJ, Greenberg CS. Effect of tissue transglutaminase on the solubility of proteins containing expanded polyglutamine repeats. J Neurochem. 2004; 88: 1253-1260.
  52. Konno T, Mori T, Shimizu H, Oiki S, Ikura K. Paradoxical inhibition of protein aggregation and precipitation by transglutaminase-catalyzed intermolecular cross-linking. J Biol Chem. 2005; 280: 17520-17525.
  53. The Huntington’s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeats that is expanded and unstable on Huntington’s disease chromosome. Cell. 1993; 72: 971-983.
  54. Banfi S, Chung MY, Kwiatkowski TJ Jr, Ranum LP, McCall AE, Chinault AC, et al. Mapping and cloning of the critical region for the spinocerebellar ataxia type 1 gene (SCA1) in a yeast artificial chromosome contig spanning 1.2 Mb. Genomics. 1993; 18: 627-635.
  55. Sanpei K, Takano H, Igarashi S, Sato T, Oyake M, Sasaki H, et al. Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT. Nat Genet. 1996; 14: 277-284.
  56. Pujana MA, Volpini V, Estivill X. Large CAG/CTG repeat templates produced by PCR, usefulness for the DIRECT method of cloning genes with CAG/CTG repeat expansions. Nucleic Acids Res. 1998; 1: 1352-1353.
  57. Fletcher CF, Lutz CM, O’Sullivan TN, Shaughnessy JD Jr, Hawkes R, Frankel WN, et al. Absence epilepsy in tottering mutant mice is associated with calcium channel defects. Cell. 1996; 87: 607-617.
  58. Vincent JB, Neves-Pereira ML, Paterson AD, Yamamoto E, Parikh SV, Macciardi F, et al. An unstable trinucleotiderepeat region on chromosome 13 implicated in spinocerebellar ataxia: a common expansion locus. Am J Hum Genet. 2000; 66: 819-829.
  59. Holmes SE, O’Hearn E, Margolis RL. Why is SCA12 different from other SCAs? Cytogenet Genome Res. 2003; 100: 189-197.
  60. Imbert G, Trottier Y, Beckmann J, Mandel JL. The gene for the TATA binding protein (TBP) that contains a highly polymorphic protein coding CAG repeat maps to 6q27. Genomics. 1994; 21: 667-668.
  61. La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature. 1991; 352: 77-79.
  62. Onodera O, Oyake M, Takano H, Ikeuchi T, Igarashi S, Tsuji S. Molecular cloning of a full-length cDNA for dentatorubral-pallidoluysian atrophy and regional expressions of the expanded alleles in the CNS. Am J Hum Genet. 1995; 57: 1050-1060.
  63. Cooper AJL, Sheu K-FR, Burke JR, Strittmatter WJ, Gentile V, Peluso G, et al. Pathogenesis of inclusion bodies in (CAG)n/Qn-expansion diseases with special reference to the role of tissue transglutaminase and to selective vulnerability. J Neurochem. 1999; 72: 889-899.
  64. Hadjivassiliou M, Maki M, Sanders DS, Williamson CA, Grunewald RA, Woodroofe NM, et al. Autoantibody targeting of brain and intestinal transglutaminase in gluten ataxia. Neurology. 2006; 66: 373-377.
  65. Boscolo S, Lorenzon A, Sblattero D, Florian F, Stebel M, Marzari R, et al. Anti transglutaminase antibodies cause ataxia in mice. PLOS ONE. 2010; 5: e9698.
  66. Stamnaes, J, Dorum S, Fleckenstein B, Aeschlimann D, Sollid LM. Gluten T cell epitope targeting by TG3 and TG6; implications for dermatitis herpetiformis and gluten ataxia. Amino Acids. 2010; 39: 1183-1191.
  67. Lerner A, Matthias T. GUT-the Trojan horse in remote organs’ autoimmunity. J Clin Cell Immunol. 2016; 7: 401.
  68. Matthias T, Jeremias P, Neidhofer S, Lerner A. The industrial food additive microbial transglutaminase, mimics the tissue transglutaminase and is immunogenic in celiac disease patients. Autoimmun Rev. 2016; 15: 1111-1119.
  69. Lerner A, Neidhofer S, Matthias T. Transglutaminase 2 and anti-transglutaminase 2 autoantibodies in celiac disease and beyond: Part A: TG2 double-edged sword: gut and extraintestinal involvement. Immunome Res. 2015; 11: 101-105.
  70. Wakshlag JJ, Antonyak MA, Boehm JE, Boehm K, Cerione RA. Effects of tissue transglutaminase on beta-amyloid 1-42-induced apoptosis. Protein J. 2006; 25: 83-94.
  71. Lee JH, Jeong J, Jeong EM, Cho SY, Kang JW, Lim J, et al. Endoplasmic reticulum stress activates transglutaminase 2 leading to protein aggregation. Int J Mol Med. 2014; 33: 849-855.
  72. Grosso H, Woo JM, Lee KW, Im JY, Masliah E, Junn E, et al. Transglutaminase 2 exacerbates α-synuclein toxicity in mice and yeast. FASEB J. 2014; 28: 4280-91.
  73. Zhang J, Wang S, Huang W, Bennett DA. Tissue transglutaminase and its product isopeptide are increased in Alzheimer’s disease and APPswe/PS1dE9 double transgenic mice brains. Mol Neurobiol. 2016; 53: 5066-5078.
  74. Wilhelmus MM, de Jager M, Smit AB, van der Loo RJ, Drukarch B. Catalytically active tissue transglutaminase colocalises with Ab pathology in Alzheimer’s disease mouse models. Sci Rep. 2016.
  75. Wilhelmus MMM, de Jager M, Rozemuller AJM, Brevé J, Bol JG, Eckert RL, et al. Transglutaminase 1 and its regulator Tazarotene-induced gene 3 localize to neuronal tau inclusions in tauopathies. J Pathol. 2012; 226: 132-142.
  76. Basso M, Berlin J, Xia L, Sleiman SF, Ko B, Haskew-Layton R, et al. Transglutaminase inhibition protects against oxidative stress-induced neuronal death downstream of pathological ERK activation. J Neurosci. 2012; 39: 6561-6569.
  77. Lee J, Kim YS, Choi DH, Bang MS, Han TR, Joh TH, et al. Transglutaminase 2 induces nuclear factor-kB activation via a novel pathway in BV-2 microglia. J Biol Chem. 2004; 279: 53725-53735.
  78. Kumar S, Mehta K. Tissue transglutaminase constitutively activates HIF-1a promoter and nuclear factor-kB via a noncanonical pathway. PLOS ONE. 2012; 7: e49321.
  79. Lu S, Saydak M, Gentile V, Stein JP, Davies PJA. Isolation and characterization of the human tissue transglutaminase promoter. J Biol Chem. 1995; 270: 9748-9755.
  80. Griffith OW, Larsson A, Meister A. Inhibition of g-glutamylcysteine synthetase by cystamine: an approach to a therapy of 5-oxoprolinuria (pyroglutamic aciduria). Biochem Biophys Res Commun. 1977; 79: 919-925.
  81. Igarashi S, Koide R, Shimohata T, Yamada M, Hayashi Y, Takano H, et al. Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch. Nat Genet 1998; 18: 111-117.
  82. Karpuj MV, Becher MW, Springer JE, Chabas D, Youssef S, Pedotti R, et al. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med. 2002; 8: 143-149.
  83. Dedeoglu A, Kubilus JK, Jeitner TM, Matson SA, Bogdanov M, Kowall NW, et al. Therapeutic effects of cystamine in a murine model of Huntington’s disease. J Neurosci. 2002; 22: 8942-8950.
  84. Lesort M, Lee M, Tucholski J, Johnson GVW. Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders. J Biol Chem. 2003; 278: 3825-3830.
  85. Dubinsky R, Gray C. CYTE-I-HD: Phase I Dose finding and tolerability study of cysteamine (cystagon) in huntington’s disease. Movement Disord. 2006; 21: 530-533.
  86. Langman CB, Greenbaum LA, Sarwal M, Grimm P, Niaudet P, Deschênes G, et al. A randomized controlled crossover trial with delayed-release cysteamine bitartrate in nephropathic cystinosis: effectiveness on white blood cell cystine levels and comparison of safety. Clin J Am Soc Nephrol. 2012; 7: 1112-1120.
  87. Besouw M, Masereeuw R, Van Den Heuvel L, Levtchenko E. Cysteamine: an old drug with new potential. Drug Discov Today. 2013; 18: 785-792.
  88. Hadjivassiliou M, Aeschlimann P, Strigun A, Sanders DS, Woodroofe N, Aeschlimann D. Autoantibodies in gluten ataxia recognize a novel neuronal transglutaminase. Ann Neurol. 2008; 64: 332-343.
  89. Krasnikov BF, Kim SY, McConoughey SJ, Ryu H, Xu H, Stavrovskaya I, et al. Transglutaminase activity is present in highly purified nonsynaptosomal mouse brain and liver mitochondria. Biochemistry. 2005; 44: 7830-7843.
  90. Menalled LB, Kudwa AE, Oakeshott S, Farrar A, Paterson N, Filippov I, et al. Genetic deletion of transglutaminase 2 does not rescue the phenotypic deficits observed in R6/2 and zQ175 mouse models of Huntington’s disease. PLOS ONE. 2014; 9: 99520-99520.
  91. Bailey CD, Johnson GV. Tissue transglutaminase contributes to disease progression in the R6/2 Huntington’s disease mouse model via aggregate-independent mechanisms. J Neurochem. 2005; 92: 83-92.
  92. Zhang J, Grosso Jasutkar H, Yan R, Woo J-M, Lee K-W, Im J-Y, et al. Transglutaminase 2 depletion attenuates a- synuclein mediated toxicity in mice. Neuroscience. 2020; 441: 58-64.
  93. Davies JE, Rose C, Sarkar S, Rubinsztein DC. Cystamine suppresses polyalanine toxicity in a mouse model of oculopharyngeal muscular dystrophy. Sci Transl Med. 2010; 2: 34-40.
  94. Bhatt MP, Lim YC, Hwang J, Na S, Kim YM, Ha KS. C-peptide prevents hyperglycemia-induced endothelial apoptosis through inhibition of reactive oxygen species-mediated transglutaminase 2 activation. Diabetes. 2013; 62: 243-253.
  95. Chrobok NL, Bol JGLM, Cornelis A, Jongenelen CA, Brevé JJP, El Alaoui S, et al. Characterization of Transglutaminase 2 activity inhibitors in monocytes in vitro and their effect in a mouse model for multiple sclerosis. PLOS ONE. 2018.